Please login to the form below

Not currently logged in
Email:
Password:

Hansa Biopharma

This page shows the latest Hansa Biopharma news and features for those working in and with pharma, biotech and healthcare.

Sarepta to assess imlifidase as pre-treatment to Duchenne muscular dystrophy gene therapy

Sarepta to assess imlifidase as pre-treatment to Duchenne muscular dystrophy gene therapy

AAV-based gene therapy for the treatment of Duchenne muscular dystrophy (DMD), the company’s partner Hansa Biopharma AB (Hansa) announced. ... LGMD). Søren Tulstrup, president and chief executive officer of Hansa, said: "We are very excited about the

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?
Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...